BofA upgraded Haemonetics (HAE) to Neutral from Underperform with a price target of $75, up from $58. Plasma volume growth returned to high single digits in the U.S. this quarter and double digits in Europe, notes the analyst, who thinks Haemonetics is taking a “more prudent view” on its guidance philosophy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target raised to $90 from $86 at Barrington
- Haemonetics price target raised to $82 from $65 at Baird
- Haemonetics Reports Improved Profitability Amid Revenue Decline
- Haemonetics: Strong Financial Performance and Strategic Adjustments Drive Buy Rating
- Haemonetics price target raised to $88 from $85 at BTIG